ChiCTR1800016100
尚未开始
/
/
/
2018-05-11
/
/
HIV infection
《接觸前預防投藥》交叉研究
《接觸前預防投藥》交叉研究
(a) compare the adherence between on-demand and daily PrEP; (b) examine the preferred regimen; (c) characterise the pattern of risk compensation following PrEP.
随机交叉对照
Ⅳ期
computer-generated random sequence
/
AIDS Trust Fund
/
90
/
1990-01-01
1990-01-01
/
1. men who have sex with men (MSM); 2. Aged 186. years old or above; 3. able to communicate in written and spoken English or Chinese; 4. inclination to engage in unprotected anal sex; 5. a history of unprotected anal sex, especially as receptive partner, within the preceding 6 months; 6. normally resident in Hong Kong; 7. referral from an HIV counselling service.;
请登录查看1. prisoner; 2. having any form of mental illnesses; 3. inability or refusal to give consent; 4. HIV positive; 5. known renal insufficiency with creatinine clearance <60mL/min; 6. known hepatitis B carrier.;
请登录查看Stanley Ho Centre for Emerging Infectious Diseases
/
Stanley Ho Centre for Emerging Infectious Diseases的其他临床试验
Stanley Ho Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong的其他临床试验
最新临床资讯
-
一项5年临床安全随访研究启示:#脐带间充质干细胞(#hUC-MSCs)
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点,索弗度肽(survodutide)成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 62
-
摩熵咨询 20 3
-
颁布机构:国家卫生健康委办公厅、 2026-11-10
-
颁布机构:国家卫健委(原国家卫计委) 2026-11-10
-
颁布机构:国家药品审评中心(CDE) 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构:国家市场监督管理总局 2026-11-07
-
颁布机构:国家市场监督管理总局 2026-11-07
-
颁布机构:国家市场监督管理总局 2026-11-04

